Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2007, Thuja Capital is an early-stage venture capital firm headquartered in Utrecht, Netherlands. The firm specializes in investing in innovative life science companies across Europe, particularly in the biotech and medtech sectors. Since its inception, Thuja Capital has focused on addressing significant unmet medical needs, supporting the translation of scientific advancements from the laboratory into clinical applications.
As of now, Thuja Capital manages over EUR 125 million (approximately $135 million) across multiple funds, including Fund I, Fund II, and Fund III, which closed in December 2021 with a total size of EUR 76 million ($86 million). The firm has a strong institutional LP base, including the European Investment Fund (EIF), ASR (a Dutch insurer), and various academic and regional investment agencies. This diverse LP base enhances their credibility and access to early-stage deal flow.
Thuja Capital has established a reputation as one of the leading venture capital firms in the Dutch life sciences sector, with a consistent presence since 2008. The firm has made a total of 40 investments, including 30 lead investments and 14 exits, showcasing its active role in the market. Their strategic partnership with Brightlands Maastricht Health Campus further strengthens their position in the life sciences ecosystem.
Thuja Capital invests primarily in early-stage life science companies, focusing on sectors such as biotechnology, diagnostics, medical devices, and digital health. The firm typically engages in pre-seed and seed stages, providing initial funding and strategic support to help startups navigate early challenges and achieve critical milestones. Their check sizes generally align with early-stage funding requirements, although specific amounts are not disclosed.
The firm emphasizes a hands-on approach, leveraging its extensive networks and advisory boards to facilitate the transition from scientific research to market-ready medical products. Thuja Capital seeks to invest in companies that demonstrate innovative solutions to pressing healthcare challenges, particularly those that can translate scientific advancements into clinical applications. Their investment strategy is characterized by strong scientific due diligence and active involvement in the development process.
Geographically, Thuja Capital focuses on the Netherlands, Belgium, and Germany, targeting a portfolio of 10-12 companies within Fund III. This geographic expansion reflects their commitment to broadening their investment scope while maintaining a focus on their core competencies in life sciences.
Thuja Capital's portfolio includes a diverse range of companies within the biotech and healthcare sectors. Notable portfolio companies include:
Thuja Capital has achieved notable exits, including the successful IPO of ArgenX and acquisitions of NightBalance, MILabs, and Okapi Biosciences. These exits underscore the firm's ability to identify and nurture high-potential companies in the life sciences sector.
Harrold van Barlingen: Managing Partner at Thuja Capital, Harrold has extensive experience in venture capital and life sciences. He has been instrumental in leading investments and guiding portfolio companies through their development phases.
Michel Briejer: Also a Managing Partner, Michel brings a wealth of knowledge in healthcare investments. His background includes significant roles in various biotech firms, contributing to Thuja's strategic direction.
Lisanne Blauw: As an Associate, Lisanne supports the investment team in sourcing and evaluating potential deals. Her expertise in life sciences enhances the firm's ability to identify promising startups.
Dieuwertje Toet: Serving as Finance Manager, Dieuwertje oversees the financial operations of the firm, ensuring efficient management of funds and resources.
To pitch to Thuja Capital, founders should utilize the preferred channel of their website at thujacapital.com or send an email to info@thujacapital.com. A comprehensive pitch deck is essential, including details about the business model, market analysis, competitive landscape, and team qualifications. Founders should expect a response time of approximately two to four weeks, depending on the volume of inquiries.
Warm introductions are preferred, especially from trusted industry contacts or existing portfolio companies. This can enhance the likelihood of receiving a favorable review of the pitch.
In December 2021, Thuja Capital closed Fund III with a total size of EUR 76 million ($86 million), marking a significant milestone for the firm. This fund aims to invest in 10-12 early-stage life science companies across the Netherlands, Belgium, and Germany.
Recent investments from Fund III include initial commitments to Alesta Therapeutics, EsoBiotec, and Pan Cancer T, all of which are focused on innovative solutions in the life sciences sector. The firm has established a strategic partnership with Brightlands Maastricht Health Campus to enhance deal flow and support for portfolio companies.
Thuja Capital has made a total of 40 investments, with 30 of those being lead investments, showcasing their active role in the early-stage venture capital landscape. The firm has achieved 14 successful exits, including notable companies such as ArgenX, which has a market cap exceeding $16.5 billion.
What are Thuja Capital's investment criteria?
Thuja Capital focuses on early-stage investments in life science companies, particularly in the biotech and medtech sectors. They seek innovative solutions that address significant unmet medical needs and demonstrate potential for clinical application.
How can founders apply or pitch to Thuja Capital?
Founders can pitch their ideas through the firm's website at thujacapital.com or by emailing info@thujacapital.com. A well-prepared pitch deck that outlines the business model, market opportunity, and team is essential.
What makes Thuja Capital different from other venture capital firms?
Thuja Capital is distinguished by its strong academic ties and extensive networks within the life sciences sector. Their hands-on support and scientific due diligence set them apart, enabling them to effectively guide portfolio companies from research to market.
What is the geographic scope of Thuja Capital's investments?
The firm primarily invests in the Netherlands, Belgium, and Germany, focusing on early-stage life science ventures within these regions.
What is the typical check size for investments?
While specific check sizes are not disclosed, Thuja Capital typically invests in early-stage rounds, which generally range from pre-seed to seed funding stages.
What is Thuja Capital's post-investment involvement like?
Thuja Capital provides hands-on support to its portfolio companies, leveraging its networks and advisory boards to assist in the development process. They are actively involved in guiding companies through their early stages and achieving key milestones.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.